Following CRL, Spectrum Drops NSCLC Drug Candidate

Spectrum Pharmaceuticals, receiving yet another blow from the FDA on its cancer therapy candidate, poziotinib, has announced that it will drop its poziotinib program and is laying off 75 percent of its research and development staff.
Source: Drug Industry Daily